Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 146 recruiting now early-phase tilt #12 of 28,963 conditions

Lung Cancer: early-phase trial registry

146 of 430 indexed Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #12 of 28,963 conditions by registered trial count.

430 US clinical trials · 146 currently recruiting · #12 of 28,963 conditions by registered trial count

Lung Cancer: 430 US clinical trials tracked, 146 recruiting.

Lung Cancer is the subject of 430 registered US clinical trials on ClinicalTrials.gov, 146 of them currently open to new participants. 23 are in Phase 3-4 (later-stage) and 181 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 36 of these trials.

Open enrollment, early-phase tilt

Lung Cancer has 430 registered US clinical trials, 146 of them open to new participants right now, about 34% of the total.

146
recruiting participants now
34%
of trials open to enrollment
23
in Phase 3-4 (later-stage)
36
top sponsor: Memorial Sloan Kettering Cancer Center

Corpus placement: #12 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Lung Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Lung Cancer is recruiting below its size-band peers.

    146 of 430 indexed trials (34%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Lung Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 36 of 430 trials (8.4%). 179 distinct sponsors appear on at least one study for this condition label.

  3. Typical Lung Cancer enrolment sits around 89 participants.

    Median target enrolment is 89 among the 410 trials that report a genuine target (sentinel values excluded). 212 of those (51.7%) plan for fewer than 100 participants.

  4. Lung Cancer research is mostly interventional.

    321 interventional and 109 observational studies make up this index (74.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 185Phase 296Phase 322Phase 41

Open and recent trials

430 total, page 1 of 9

RECRUITING open-ended (no fixed target)

Integrated Cancer Repository for Cancer Research

University of Nebraska

NCT02012699

RECRUITING 25,000 participants

Avera Cancer Sequencing and Analytics Protocol (ASAP)

Avera McKennan Hospital & University Health Center

NCT05142033

RECRUITING 15,000 participants

Molecular and Genetic Analysis of Lung Cancer

Massachusetts General Hospital

NCT03029325

RECRUITING 10,850 participants

Lung Cancer Biomarkers and Screening

NYU Langone Health

NCT00301119

RECRUITING open-ended (no fixed target)

UNC Pleural Fluid Registry

UNC Lineberger Comprehensive Cancer Center

NCT05620329

RECRUITING 9,600 participants

Sample Collection for Ongoing Research and Product Evaluation Study

Natera

NCT07318051

RECRUITING NA 9,460 participants

Centralized Screening Unit (CSU) at Montefiore-Einstein

Albert Einstein College of Medicine

NCT06284408

RECRUITING 7,200 participants

PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification

M.D. Anderson Cancer Center

NCT05049837

RECRUITING 7,000 participants

Evaluation for NCI Surgery Branch Clinical Research Protocols

National Cancer Institute (NCI)

NCT00001823

RECRUITING 7,000 participants

Thoracic Specimen Registry

Mayo Clinic

NCT04118660

RECRUITING 6,000 participants

Detection of Genetic Markers of Lung Cancer

University of Pittsburgh

NCT00280202

RECRUITING NA 5,515 participants

Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital

Washington University School of Medicine

NCT07146568

RECRUITING 5,000 participants

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Dana-Farber Cancer Institute

NCT05463796

RECRUITING 4,000 participants

Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer

Vanderbilt-Ingram Cancer Center

NCT00897117

RECRUITING 3,000 participants

Real World Registry for Use of the Ion Endoluminal System

Intuitive Surgical

NCT06004440

RECRUITING NA 2,869 participants

Enhancing Lung Cancer Screening Through Human-Centered Intervention

University of California, Davis

NCT06351085

RECRUITING 2,400 participants

Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier

Veracyte

NCT06426628

RECRUITING 2,122 participants

WTC Chest CT Imaging Archive

Icahn School of Medicine at Mount Sinai

NCT03295279

RECRUITING 2,000 participants

Health Opportunities and Promoters of Equitable Screening for Lung Cancer

Massachusetts General Hospital

NCT05784922

RECRUITING 2,000 participants

Multiparametric Image Analysis and Correlation With Outcomes in Lung Cancer Screening and Early Stage Lung Cancer

University of Texas Southwestern Medical Center

NCT03563976

RECRUITING 2,000 participants

Cough Capture as a Portal Into the Lung

Albert Einstein College of Medicine

NCT05854563

RECRUITING NA 1,753 participants

Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer

University of California, Irvine

NCT07062172

RECRUITING 1,750 participants

Collection of Blood From Patients With Cancer

National Cancer Institute (NCI)

NCT00034216

RECRUITING NA 1,500 participants

Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT

Massachusetts General Hospital

NCT06910956

RECRUITING Phase 3 1,410 participants

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Pfizer

NCT07222566

RECRUITING 1,400 participants

EXoPERT EMERALD Clinical Study

EXoPERT

NCT07186296

RECRUITING 1,250 participants

Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT05995821

RECRUITING NA 1,232 participants

Empathic Communication Skills (ECS) Training

Memorial Sloan Kettering Cancer Center

NCT05456841

RECRUITING NA 1,160 participants

Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54

Wake Forest University Health Sciences

NCT04577599

RECRUITING 1,100 participants

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

National Cancer Institute (NCI)

NCT01441089

RECRUITING 1,000 participants

Next Generation Chest X-Ray Tomosynthesis for Screening of Lung Cancer

University of California, San Diego

NCT06577883

RECRUITING NA 1,000 participants

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

Dana-Farber Cancer Institute

NCT06716580

RECRUITING NA 900 participants

Lung Cancer Screening in High-risk Black Individuals

Massachusetts General Hospital

NCT05898594

RECRUITING 800 participants

Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer

University of California, Davis

NCT00899405

RECRUITING Phase 3 800 participants

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

Roswell Park Cancer Institute

NCT06563388

RECRUITING 750 participants

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

National Cancer Institute (NCI)

NCT00451022

RECRUITING 750 participants

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer

University of Maryland, Baltimore

NCT07008664

RECRUITING 700 participants

Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

University of Colorado, Denver

NCT00900419

RECRUITING NA 675 participants

Health Education Approach to Lung Screening

Virginia Commonwealth University

NCT06070870

RECRUITING NA 625 participants

Comprehensive Outcomes for After Cancer Health

Pack Health

NCT05349227

RECRUITING 600 participants

A Registry for People With Lung Cancer

Memorial Sloan Kettering Cancer Center

NCT06424327

RECRUITING NA 500 participants

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

UNC Lineberger Comprehensive Cancer Center

NCT06896162

RECRUITING 500 participants

Collection of Sputum and Labeling for Lung Cancer

bioAffinity Technologies

NCT03457415

RECRUITING 500 participants

Investigating Hereditary Risk In Thoracic Cancers (INHERIT)

Dana-Farber Cancer Institute

NCT05587439

RECRUITING Phase 2 497 participants

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Apollomics

NCT03175224

RECRUITING NA 480 participants

Tribally Engaged Approaches to Lung Screening (TEALS)

University of Oklahoma

NCT04948060

RECRUITING Phase 1 470 participants

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

SystImmune

NCT05983432

RECRUITING Phase 1 416 participants

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Bristol-Myers Squibb

NCT06618287

RECRUITING NA 400 participants

Adaptive Symptom Self-Management Immunotherapy Study

University of Arizona

NCT05715255

RECRUITING NA 397 participants

Stereotactic Magnetic Resonance Guided Radiation Therapy

Dana-Farber Cancer Institute

NCT04115254

Page 1 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 85
Phase 2 96
Phase 3 22
Phase 4 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What is open for Lung Cancer right now

146 recruiting of 430 indexed (34% open).

Phase mix: 23 late (III/IV) vs 181 early (I/II) (early-phase heavy).

Top sponsor: Memorial Sloan Kettering Cancer Center (36 trials), 9 others listed. 50 shown below, recruiting first. #12 of 28,963 conditions by registered trial count.

How open-enrollment share is computed

Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.

Frequently Asked Questions

How many clinical trials are there for Lung Cancer?

PlainTrial tracks 430 US clinical trials for Lung Cancer, of which 146 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Lung Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.